Wire-Interwoven Nitinol Stent Outcome in the Superficial Femoral and Proximal Popliteal Arteries

Author:

Garcia Lawrence1,Jaff Michael R.1,Metzger Christopher1,Sedillo Gino1,Pershad Ashish1,Zidar Frank1,Patlola Raghotham1,Wilkins Robert G.1,Espinoza Andrey1,Iskander Ayman1,Khammar George S.1,Khatib Yazan1,Beasley Robert1,Makam Satyaprakash1,Kovach Richard1,Kamat Suraj1,Leon Luis R.1,Eaves William Britton1,Popma Jeffrey J.1,Mauri Laura1,Donohoe Dennis1,Base Carol C.1,Rosenfield Kenneth1

Affiliation:

1. From the Division of Cardiology, St. Elizabeth Medical Center, Tufts University School of Medicine, Boston, MA (L.G.); Division of Cardiology, Massachusetts General Hospital, Boston (M.R.J., K.R.); Division of Cardiology, Wellmont Holston Valley Medical Center, Kingsport, TN (C.M.); CardioVascular Solutions Institute, Bradenton, FL (G.S.); Division of Cardiology, Banner Good Samaritan Medical Center, Phoenix, AZ (A.P.); Austin Heart, P.A., TX (F.Z.); Cardiovascular Institute of the South, Lafayette,...

Abstract

Background— Stent-based therapy in the superficial femoral and popliteal arteries in patients with peripheral artery disease i s compromised by restenosis and risk of stent fracture or distortion. A novel self-expanding nitinol stent was developed that incorporates an interwoven-wire design (Supera stent, IDEV Technologies, Inc, Webster, TX) to confer greater radial strength, flexibility, and fracture resistance. Methods and Results— This prospective, multicenter, investigational device exemption, single-arm trial enrolled 264 patients with symptomatic peripheral artery disease undergoing percutaneous treatment of de novo or restenotic lesions of the superficial femoral or proximal popliteal (femoropopliteal) artery. Freedom from death, target lesion revascularization, or any amputation of the index limb at 30 days (+7 days) postprocedure was achieved in 99.2% (258/260) of patients ( P <0.001). Primary patency at 12 months (360±30 days) was achieved in 78.9% (180/228) of the population ( P <0.001). Primary patency by Kaplan–Meier analysis at 12 months (360 days) was 86.3%. No stent fracture was observed by independent core laboratory analysis in the 243 stents (228 patients) evaluated at 12 months. Clinical assessment at 12 months demonstrated improvement by at least 1 Rutherford–Becker category in 88.7% of patients. Conclusions— The SUPERB Trial, an investigational device exemption study using an interwoven nitinol wire stent in the femoropopliteal artery, achieved the efficacy and safety performance goals predesignated by the Food and Drug Administration. On the basis of the high primary patency rate, absence of stent fracture, and significant improvements in functional and quality-of-life measures, the Supera stent provides safe and effective treatment of femoropopliteal lesions in symptomatic patients with peripheral artery disease. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT00933270.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

Reference31 articles.

1. Peripheral Arterial Disease Detection, Awareness, and Treatment in Primary Care

2. Centers for Disease Control and Prevention. Division of Heart Diseases and Stroke Prevention. Peripheral artery disease (PAD) fact sheet. http://www.cdc.gov/dhdsp/data_statistics/fact_sheets/fs_pad.htm. Accessed July 22 2013.

3. American Heart Association. Heart Disease and Stroke Statistics—2013 Update. http://circ.ahajournals.org/content/127/1/e6.full.pdf+html. Accessed July 22 2013.

4. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)

5. Limitations of Percutaneous Transluminal Angioplasty and Stenting for the Treatment of Disease of the Superficial Femoral and Popliteal Arteries

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3